Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Surgery. 2021 Jan;169(1):145-149. doi: 10.1016/j.surg.2020.03.026. Epub 2020 May 12.
Outpatient adrenalectomy has the potential to decrease costs, improve inpatient capacity, and decrease patient exposure to hospital-acquired conditions. Still, the practice has yet to be widely adopted and current studies demonstrating the safety of outpatient adrenalectomy are limited by sample size, extensive exclusion criteria, and no comparison to inpatient cases. We aimed to study the characteristics and safety of outpatient adrenalectomy using the largest such sample to date across 2 academic medical centers and 3 minimally invasive approaches.
All minimally invasive adrenalectomies were identified, starting from the time outpatient adrenalectomy was initiated at each institution. Cases involving removal of other organs, bilateral adrenalectomies, and cases in which a patient was admitted to the hospital before the day of surgery were excluded. Patient, tumor, and case characteristics were compared between outpatient and inpatient cases, and multivariable regression analysis was used to assess odds of 30-day readmission and/or complication.
Of 203 patients undergoing minimally invasive adrenalectomy, 49% (n = 99) were performed on an outpatient basis. Outpatient disposition was more likely in the setting of lower estimated blood loss, case completion before 3 pm, and for surgery performed in the setting of nodule/mass and primary hyperaldosteronism versus Cushing's syndrome, pheochromocytoma, and metastasis (P < .05). There were no significant differences in patient age, body mass index, American Society of Anesthesiologists class, procedure performed, or total time under anesthesia between inpatient and outpatient cases. On adjusted analysis, outpatient adrenalectomy was not associated with increased 30-day readmission rate (odds ratio 0.23 [confidence interval 0.04-1.26] P = .09) or 30-day complication rate (odds ratio 0.21 [confidence interval 0.06-0.81] P = .02).
Outpatient adrenalectomy can be performed safely without increased risk of 30-day complications or readmission in appropriately selected candidates.
门诊肾上腺切除术有可能降低成本、提高住院容量,并减少患者接触医院获得性疾病的机会。尽管如此,这种做法尚未得到广泛采用,目前证明门诊肾上腺切除术安全性的研究受到样本量、广泛排除标准和没有与住院病例比较的限制。我们的目的是使用目前为止在 2 家学术医疗中心和 3 种微创方法中进行的最大规模的此类样本,研究门诊肾上腺切除术的特点和安全性。
从每个机构开始进行门诊肾上腺切除术时,确定所有微创肾上腺切除术。排除涉及切除其他器官、双侧肾上腺切除术以及患者在手术前一天住院的病例。比较门诊和住院病例的患者、肿瘤和病例特征,并使用多变量回归分析评估 30 天内再入院和/或并发症的几率。
在 203 例接受微创肾上腺切除术的患者中,有 49%(n=99)在门诊进行。门诊处置更可能发生在估计出血量较低、手术在下午 3 点前完成的情况下,以及在结节/肿块和原发性醛固酮增多症的情况下进行手术,而不是库欣综合征、嗜铬细胞瘤和转移的情况下(P<.05)。门诊和住院病例的患者年龄、体重指数、美国麻醉医师协会分级、手术方式或全身麻醉总时间无显著差异。在调整分析中,门诊肾上腺切除术与 30 天内再入院率(优势比 0.23[置信区间 0.04-1.26]P=0.09)或 30 天内并发症率(优势比 0.21[置信区间 0.06-0.81]P=0.02)增加无关。
在适当选择的患者中,门诊肾上腺切除术是安全的,不会增加 30 天内并发症或再入院的风险。